Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide Clinical Utility in T1DM and T2DM
NCT00108004Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2003
- Primary completion
- Jun 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pramlintide in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoints: Clinical Utility at 6 months, Safety at 6 months and 4 more. Started Apr 2003; status: completed.
02
Drugs
pramlintide
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00108004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00108004.